Phathom Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

BUFFALO GROVE, Ill.–(BUSINESS WIRE)–Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the closing of its previously announced initial public offering of 10,997,630 shares of its common...

Input your search keywords and press Enter.